1. Introduction {#sec1}
===============

Coronaviruses (CoVs) affecting upper respiratory tract were first identified in humans in mid-1960 ([@bib34]). In late 2002, there was emergence of a life threatening CoV of atypical pneumonia, named severe acute respiratory syndrome CoV (SARS-CoV). SARS-CoV belongs to the family *Coronaviridae*, and is an enveloped, positive-stranded RNA virus with ∼30,000 nucleotides ([@bib26]). Its genome encodes two polyproteins, pp1a (∼490 kDa) and pp1ab (∼790 kDa) which are processed by 3C-like protease (3CL^pro^) and papain-like protease (PL^pro^) to generate non-structural proteins essential for viral replication ([@bib30], [@bib31]). Due to its vital role in replication, 3CL^pro^ has been regarded as a validated drug target. Many inhibitors of SARS-CoV 3CL^pro^ were discovered by high throughput screening and structure-based rational design as summarized in the review articles ([@bib10], [@bib16], [@bib18], [@bib24], [@bib25], [@bib33], [@bib38]). After SARS-CoV infection subsided, Middle East respiratory syndrome CoV (MERS-CoV), has emerged in Saudi Arabia in 2012 and spread worldwide, killing 36% of the reported 1826 patients (<http://www.who.int/mediacentre/factsheets/mers-cov/en/>). Due to the similar maturation pathway, MERS-CoV 3CL^pro^ is also regarded as a target for developing antiviral drugs ([@bib32]). Though tremendous efforts have been made to develop inhibitors, therapeutic interventions for such continuous CoV outbreaks are yet to reach market ([@bib4], [@bib14]).

These CoVs\' 3CL^pro^ are functionally similar to the 3C^pro^ in picornaviruses and both adopt chymotrypsin fold ([@bib3]). However, 3CL^pro^ is a dimer with Cys-His dyad, whereas 3C^pro^ is a monomer with Cys-His-Glu triad ([@bib11], [@bib21], [@bib36]). Picornaviruses are small, non-enveloped RNA virus with genome size of 7500--8000 nucleotides. Based on their genetic organization, the family is composed of 31 genera including *Enterovirus* (enterovirus and rhinovirus), *Aphthovirus* (foot-and-mouth disease virus), *Cardiovirus* (encephalomyocarditis virus), *Hepatovirus* (hepatitis A virus) and others (<http://www.picornaviridae.com/>). As 3C^pro^ is produced in all genera of *Picornaviridae* virus family, its inhibitors showed broad-spectrum, potent antiviral activity against rhinovirus, coxsackievirus and enterovirus ([@bib13], [@bib15], [@bib28]). Though 3C^pro^ and 3CL^pro^ share similar structures at their active sites, subtle differences often discriminate inhibitors. AG7088, an established 3C^pro^ inhibitor, was inactive against SARS-CoV 3CL^pro^ prior to the modifications ([@bib9], [@bib27], [@bib29], [@bib37]). Unlike AG7088 which contains α, β-unsaturated ester for forming covalent bond with the active-site Cys, our previously reported potent peptidomimetic inhibitors of 3C^pro^ from enterovirus 71 (EV71) contains aldehyde as electrophilic warhead ([@bib20]). In this work, we screened those EV71 3C^pro^ inhibitors against MERS-CoV 3CL^pro^ and further evaluated the hits by cell-based assays using live MERS-CoV. Our best compounds **6b**, **6c** and **6d** inhibited MERS-CoV 3CL^pro^ with IC~50~ values ranging from 1.7 to 4.7 μM and also suppressed viral replication with EC~50~ values between 0.6 and 1.4 μM. These derivatives represent some of few cell-based assay-confirmed anti-MERS-CoV agents and also showed broad-spectrum activity against both α- and β-types of CoVs as described herein.

2. Materials and methods {#sec2}
========================

2.1. Synthesis of compounds {#sec2.1}
---------------------------

Compounds reported here were synthesized using previously reported procedures with some modifications ([@bib20]). Test compounds and gemcitabine hydrochloride (GEM; Sigma-Aldrich, St. Louis, MO) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at 50 μM concentration.

2.2. Viruses and cells {#sec2.2}
----------------------

Patient-derived isolate MERS-CoV (MERS-CoV/KOR/KNIH/002_05_2015; GenBank accession No. KT029139) was provided by the Korea Center for Disease Control and Prevention. Huh-7 and Vero cells (Cat. No. CCL-81) were obtained from Prof. D.-E. Kim at Konkuk University (Seoul, Republic of Korea) and American Type Culture Collection (ATCC, Manassas, VA), respectively. The cells were maintained in Dulbecco\'s Modified Eagle Medium (DMEM; Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Gibco BRL) at 37 °C and 5% CO~2~. To minimize adaptive mutation probability of MERS-CoV to another species during passage, MERS-CoV was amplified by infection of a human cell line, Huh-7 cells. The infectious viral titers from culture supernatants at day 2 post-infection (p.i.) were measured by a plaque assay using Vero cells according to other reports ([@bib5], [@bib6]). MERS-CoV was maintained under biosafety level 3 conditions in Korea Research Institute of Chemical Technology (KRICT).

Human CoV strains, 229E (Cat. No. VR-740) and OC43 (Cat. No. VR-1558) were purchased from ATCC. They were amplified by infecting human fetal lung fibroblast MRC-5 cells (ATCC, Cat. No. CCL-171). Feline infectious peritonitis coronavirus (FIPV) strain (Cat. No. VR-990) and its host cell line Crandall feline kidney (CRFK) (Cat. No. 10094) were obtained from ATCC and Korean Cell Line Bank (Seoul, Republic of Korea), respectively.

2.3. Expression and purification of SARS- and MERS-CoV 3CL^pro^ {#sec2.3}
---------------------------------------------------------------

The expression and purification of SARS-CoV 3CL^pro^ followed our reported procedure ([@bib19]). For expression of MERS-CoV 3CL^pro^ ([@bib17]), the Factor Xa cleavage site (IEGR) and the 3CL^pro^ (accession [KJ361502.1](http://KJ361502.1){#interref0010}, Ser3248--Gln3553) DNA sequence was synthesized and cloned into the pET32 expression vector by Mission Biotech. Company (Taiwan) and was transformed into *E. coli* BL21 (DE3). A 10 ml overnight culture of a single transformant was used to inoculate 1L of fresh LB medium containing 100 μg/ml ampicillin. The cells were grown at 37 °C to A~600~ = 0.8 and induced with 0.4 mM isopropyl-β-thiogalactopyranoside (IPTG) for 22 h at 16 °C. The cells were harvested by centrifugation at 7000 × *g* for 15 min and the pellet was suspended in lysis buffer (12 mM Tris-HCl, 120 mM NaCl, 0.1 mM EDTA, and 5 mM DTT, pH 7.5). A French-press instrument (Constant Cell Disruption System) was used to disrupt the cells at 20,000 psi and centrifuged at 20,000 × *g* for 1 h to discard the debris. The cell-free extract was loaded onto Ni-NTA column which was equilibrated with lysis buffer containing 5 mM imidazole. After exhaustive washing with lysis buffer, the imidazole concentration of the washing buffer was increased to 30 mM. The protein eluted by lysis buffer containing 300 mM imidazole was dialyzed against lysis buffer to remove imidazole and then Factor Xa was added to a final concentration of 1% (w/w) and incubated at 16 °C for 24 h to remove the His-tag. Subsequently, the processed MERS-CoV 3CL^pro^ was passed through a Ni-NTA column for purification. The protein concentration was determined by the protein assay kit (BioRad, USA) and BSA was used as standard.

2.4. Measurement of IC~50~ {#sec2.4}
--------------------------

A fluorometric assay by using the fluorogenic peptide, Dabcyl-KTSAVLQSGFRKME-Edans as previously described ([@bib19]) was used to determine the inhibition constants of compounds. The enhanced fluorescence due to the cleavage of this substrate catalyzed by the 3CL^pro^ was monitored at 538 nm with excitation at 355 nm. The IC~50~ value of individual sample was measured in a reaction mixture containing 50 nM SARS-CoV 3CL^pro^ or 0.3 μM MERS-CoV 3CL^pro^ and 10 μM of the fluorogenic substrate in 20 mM Bis-Tris (pH 7.0).

2.5. Cytopathic effect inhibition assay {#sec2.5}
---------------------------------------

Huh-7 cells were seeded in 96-well plates (2 × 10^4^ cells per well). On the next day, cells were infected with MERS-CoV at a multiplicity of infection (MOI) of 0.1 in DMEM without FBS for 1 h. After washing with PBS, mock-infected or virus-infected cells were treated with 3-fold serial dilutions of test compounds or GEM used as a positive control. At day 2 p.i., cell lysate was harvested for measuring cell viability using the CellTiter 96^®^ AQ~ueous~ One Solution Cell Proliferation Assay according to the manufacturer\'s instructions (Promega, Madison, WI). The 50% cytotoxic concentration (CC~50~) and 50% effective concentration (EC~50~) values were calculated using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA). Antiviral assay for other CoVs, including 229E, OC43 and FIPV strains, were performed as mentioned above by using different cell lines. MRC-5 cells were used for culturing human CoVs, 229E and OC43, while CRFK cells for feline CoV, FIPV.

2.6. Western blot analysis {#sec2.6}
--------------------------

Huh-7 cells seeded in 6-well plates (3 × 10^5^ cells per well) were infected with MERS-CoV at an MOI of 0.02 for 1 h. After washing with PBS, cells were treated with 0.1, 1 and 10 μM of compounds **6b**, **6c** and **6d**. In parallel, 0.02% DMSO was treated as a compound vehicle. On day 1 p.i., 30 μg cell lysates suspended in sample loading buffer (Biosesang, Gyeonggi-do, Republic of Korea) were subjected to 10% SDS-PAGE and electro-transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA). MERS-CoV NP was detected using a primary antibody specific for viral nucleocapsid protein (NP) (Cat. 100211-RP02; Sino Biological Inc., Beijing, China), followed by a horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (Thermo Scientific, Waltham, MA). The cellular β-actin protein, a loading control, was detected with an anti-β-actin-specific primary antibody (Cat. No. A1987; Sigma-Aldrich) and the HRP-conjugated goat anti-mouse secondary antibody (Thermo Scientific). After addition of a chemiluminescent HRP substrate (SuperSignal West Pico Chemiluminescent Substrate; Pierce, Rockford, IL), images were obtained using a LAS-4000 Luminescent Image Analyzer (Fujifilm, Tokyo, Japan).

2.7. Plaque inhibition assay {#sec2.7}
----------------------------

Huh-7 cells were inoculated in 6-well plates at a density of 1 × 10^6^ cells per well for 1 day. Culture supernatants treated with 1 μM compounds were harvested at day 1 p.i. They were serially diluted 10-fold in DMEM from 10^−1^ to 10^−3^ and 1 ml of each sample was used to infect Vero cells for 1 h. After washing with PBS to remove unabsorbed virus, DMEM containing 0.5% agarose (overlay medium) was added. On day 3 p.i., plaques were visualized with 50 μg/ml neutral red (Sigma-Aldrich).

3. Results and discussion {#sec3}
=========================

3.1. Inhibition of MERS-CoV 3CL^pro^ and viral infection by **6b**, **6c** and **6d** {#sec3.1}
-------------------------------------------------------------------------------------

Peptidomimetic compounds were synthesized according to our reported method ([@bib20]). Preliminary screening of these peptidomimetic compounds against MERS 3CL^pro^ were done at 50 μM. Compounds inhibiting more than half of the protease activity under such condition were selected for further IC~50~ measurements. Using enzymatic assay, the compounds **6b**, **6c** and **6d** showed IC~50~ of 2.4, 4.7 and 1.7 μM against purified 3CL^pro^ of MERS-CoV, respectively ([Table 1](#tbl1){ref-type="table"} ). These compounds also inhibited SARS 3CL^pro^ at lower IC~50~ values of 0.7, 0.5 and 0.2 μM, respectively.Table 1Enzymatic and cell-based antiviral assays of selected compounds.Table 1CompdArRIC~50~ (μM)CC~50~ (μM)[a](#tbl1fna){ref-type="table-fn"}EC~50~ (μM) MERS-CoVS.I.[b](#tbl1fnb){ref-type="table-fn"}MERS-CoV 3CL^pro^SARS --CoV 3CL^pro^**4a**3,4-(OCH~2~O)C~6~H~3~---COOCH~3~\>25\>25ND[c](#tbl1fnc){ref-type="table-fn"}NDND**5a**3,4-(OCH~2~O)C~6~H~3~---CH~2~OH\>25\>25NDNDND**6a**3,4-(OCH~2~O)C~6~H~3~---CHO\>25\>25\>100\>100ND**6b**3-BrC~6~H~4~---CHO2.4 ± 0.30.7 ± 0.2\>1001.4 ± 0.0\>71.4**6c**4-Me~2~NC~6~H~4~---CHO4.7 ± 0.60.5 ± 0.1\>1001.2 ± 0.6\>83.3**6d**4-Cl,2-FC~6~H~3~---CHO1.7 ± 0.30.2 ± 0.0758.6 ± 1.20.6 ± 0.097.9GEM[d](#tbl1fnd){ref-type="table-fn"}----NDND\>1008.3 ± 0.9\>12.1[^2][^3][^4][^5]

To evaluate the ability of these compounds to block viral replication, we performed cytopathic inhibition assay using MERS-CoV-infected Huh-7 cells. As shown in [Fig. 1](#fig1){ref-type="fig"} , compounds **6b**, **6c** and **6d** efficiently suppressed viral replication with EC~50~ of 1.4, 1.2 and 0.6 μM, respectively ([Table 1](#tbl1){ref-type="table"}). Though it is usual to see EC~50~ higher than IC~50~, due to the presence of membrane barrier, we observed EC~50~ to be smaller than IC~50~. This could be due to the higher concentration (300 nM) used for *in-vitro* enzymatic assay because it is a weakly associated dimer ([@bib32]). In fact, they inhibited 50 nM SARS 3CL^pro^, a tight dimer, in the submicromolar range ([Table 1](#tbl1){ref-type="table"}). These compounds had CC~50~ larger than 100 μM for **6b** and **6c** or 58.6 μM for **6d** against uninfected cells, resulting in selectivity index (S.I.) values larger than 71.4. As expected, compound **6a** which was inactive in the enzyme assay did not suppress viral replication. GEM, used as a positive control according to a previous report ([@bib7]), was less potent in inhibiting MERS-CoV infection with an EC~50~ value of 8.3 μM. It also showed marginal toxicity and thus decreased viability of mock cells by 20% or more at the concentrations above 3.7 μM ([Table 1](#tbl1){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}).Fig. 1**Antiviral activity of 6b, 6c and 6d against MERS-CoV in Huh-7 cells.** Huh-7 cells in 96-well plates were mock-infected or infected with MERS-CoV at an MOI of 0.1 for 1 h at 37 °C. After washing with PBS, cells were treated with 3-fold serial dilutions of test compounds (**6a**, **6b**, **6c** and **6d**) or a control compound (GEM). On day 2 p.i., cell lysates were harvested for measuring cell viability. The data represent the means ± standard deviations from three independent experiments.Fig. 1

3.2. Suppression of viral protein production and infectious MERS-CoV generation {#sec3.2}
-------------------------------------------------------------------------------

To confirm that the observed antiviral activity of compounds **6b**, **6c** and **6d** reflects inhibition of MERS-CoV infection, both viral protein and progeny production was measured after treatment of virus-infected cells with these compounds. Western blot analysis showed that viral NP was decreased by these inhibitors in a dose-dependent manner ([Fig. 2](#fig2){ref-type="fig"} ). It is noteworthy that no viral NP detectable in the presence of 10 μM 3CL^pro^ inhibitors.Fig. 2**Inhibition of MERS-CoV NP production by 6b, 6c and 6d in a dose-dependent manner.** Huh-7 cells in 6-well plates were infected with MERS-CoV at an MOI of 0.02 for 1 h at 37 °C.The virus-infected cells were treated with increasing concentrations (0.1, 1 and 10 μM) of each compound. Co-treatment of interferon-alpha 2A (IFN; 50 ng/ml) and ribavirin (RBV; 100 μM) was used as a positive control. On day 1 p.i., cells were harvested and loaded to 10% SDS-PAGE (30 μg per well). Immunoblotting was performed using rabbit anti-NP antibody and HRP-conjugated goat anti-rabbit secondary antibody. β-Actin was used as a loading control.Fig. 2

We further compared the number of infectious MERS-CoV particles in the culture supernatants, both in the presence and absence of 3CL^pro^ inhibitors. The plaque assay showed that the viral titer in the absence of compound was 4.4 × 10^5^ plaque forming units (pfu)/ml, but reduced to 1.7 × 10^4^, 2.9 × 10^4^, and 1.2 × 10^4^ pfu/ml by 1 μM of compounds **6b**, **6c** and **6d**, respectively ([Fig. 3](#fig3){ref-type="fig"} ). Taken together, the results suggest that the compounds originally selected as EV71 3C^pro^ blockers efficiently inhibited MERS-CoV 3CL^pro^ activity and suppressed viral protein production as well as viral progeny generation. The data also indicate that the inhibitors can penetrate virus-infected cell membrane to reach the active site of 3CL^pro^.Fig. 3**Downregulation of MERS-CoV progeny generation by 3CL**^**pro**^**inhibitors, 6b, 6c and 6d.** MERS-CoV-infected Huh-7 cells in 6-well plates were treated with 1 μM **6b**, **6c** and **6d** for 1 day. Culture supernatants were harvested and serially diluted by 10-fold in DMEM (10^−1^ to 10^−3^). Fresh Vero cells in 6-well plates were infected with the diluted cell culture inoculum for 1 h. And the number of infectious viral particles was counted by addition of the overlay medium for 3 days and by neutral red staining.Fig. 3

3.3. In silico molecular docking of **6d** against MERS-CoV 3CL^pro^ {#sec3.3}
--------------------------------------------------------------------

To rationalize potent inhibition, we docked **6d** into the active site of MERS-CoV 3CL^pro^. The initial pose of the complex was generated based on the X-ray structure (PDB code: [4RSP](pdb:4RSP){#intref0025}) of the 3CL^pro^ in complex with a covalent inhibitor ([@bib32]) and those of the human rhinovirus 3C^pro^ bound with irreversible inhibitors ([@bib22], [@bib35]). Then, the simulation was done by Discovery Studio (Accelrys Inc., San Diego, CA). A Cys at subsite S1 of 3CL^pro^ acts as a nucleophile to cleave substrates by attacking carbonyl carbon of the amide bond between the conserved Gln at P1 and the small amino acids such as Ser, Ala or Gly at P1\' ([@bib8], [@bib23]). Our modelling shows that the γ-sulfur of Cys148 forms a covalent bond with the **6d** aldehyde carbon and the resulting oxyanion is stabilized by His41 ([Fig. 4](#fig4){ref-type="fig"} ). A cyclic lactam moiety with *cis*-amide geometry on binding to 3C^pro^ was proposed to mimic the P1 Gln of peptide substrates ([@bib22]). Based on our docking results, the P1 lactam moiety of **6d** binds to S1 subsite of 3CL^pro^ by forming H-bonds with His166 and Glu169. The P2 phenylalanine moiety prefers to occupy S2 subsite. The cinnamoyl group of **6d** occupies S3 and may be extended to S4. The amide group between phenylalanine and cinnamoyl group further forms H-bonds with Gln192 and Glu169. We also docked **6d** based on the apo-form MERS-CoV 3CL^pro^ structure (PDB code: [5c3n](pdb:5c3n){#intref0030}) ([@bib12]). Since the free-form and ligand-bound structures showed no significant difference in the active site, the binding modes of **6d** in these two structures are indeed very similar (data not shown).Fig. 4**Docking of inhibitor 6d with MERS-CoV 3CL**^**pro**^. Cys148 of the protease makes a covalent bond with the carbonyl carbon of the inhibitor aldehyde, forming a stable tetrahedral species (the inset), and the resulting oxyanion being stabilized by His 41. The protease is shown in a charge-potential surface. The putative substrate-binding subsites S1′, S1, S2, S3 and S4 are indicated. Moreover, the possible hydrogen bonds of **6d** to the protease are further drawn with dashed lines.Fig. 4

From our experimental as well as modelling results, substituents on cinnamoyl groups of these peptidomimetic inhibitors seem to be critical for the activity. Substituent *p-*chloro in **6d** makes halogen bonding with His194, leading to better potency. Compound **6b** and **6c** with slightly bulkier *m*-bromo and *p*-dimethylamino moiety, respectively, displayed approximately 2-fold drop in IC~50~. Compound **6a** with the bulkiest 3,4-methylenedioxy substituent failed to inhibit the 3CL^pro^ even at 25 μM. Compounds **4a** and **5a** that lacked aldehyde warhead failed to inhibit 3CL^pro^, emphasizing the importance of reactive aldehyde electrophile.

3.4. Broad spectrum activity against human and feline CoVs {#sec3.4}
----------------------------------------------------------

To investigate for broad spectrum activity, three compounds were tested against human and feline CoVs. The result showed both α-CoVs, human 229E strain and FIPV, and β-CoV (human OC43 strain) were sensitive to the compounds with EC~50~ of 1.1--17.7 μM ([Table 2](#tbl2){ref-type="table"} ), suggesting potent and broad-spectrum antiviral activities of these 3CL^pro^ inhibitors. The CC~50~ values measured using MRC-5 and CRFK cells, used to cultivate human and feline CoVs, respectively, were found to be more than 100 μM. Therefore, the S.I. values were ranged above 5.7 as shown in parentheses.Table 2Antiviral activity of **6b**, **6c**, and **6d** against 229E, OC43 and FIP.Table 2CompdCC~50~[a](#tbl2fna){ref-type="table-fn"} (μM)EC~50~ (μM)\
(S.I)229E[b](#tbl2fnb){ref-type="table-fn"}OC43[c](#tbl2fnc){ref-type="table-fn"}FIPV[d](#tbl2fnd){ref-type="table-fn"}**6b**\>1004.3 ± 0.1\
(\>25.0)13.5 ± 0.8\
(\>7.3)2.5 ± 1.1\
(\>40.0)**6c**\>1004.2 ± 0.3\
(\>23.8)16.8 ± 0.3\
(\>6.0)1.9 ± 0.2\
(\>52.6)**6d**\>1002.0 ± 0.2\
(\>50.0)17.7 ± 1.6\
(\>5.7)1.1 ± 0.3\
(\>90.9)[^6][^7][^8][^9]

Peptide and peptidomimetic aldehyde inhibitors against 3CL^pro^ have been reported ([@bib2], [@bib1], [@bib39]) but not tested on live CoVs. However, a potent SARS-CoV 3CL^pro^ peptidomimetic aldehyde inhibitor, TG-0205221, has been shown to block SARS-CoV and human CoV 229E replications ([@bib37]). As shown in this study, we have identified potent and membrane-permeable MERS-CoV inhibitors **6b**, **6c** and **6d** using live MERS-CoV virus with EC~50~ of 0.6--1.2 μM and S.I. over 71.4. These compounds with IC~50~ \< 0.5 μM against 3C^pro^ ([@bib20]) inhibited 3CL^pro^ of MERS-CoV with IC~50~ of 1.7--4.7 μM and SARS-CoV with IC~50~ of 0.2--0.7 μM. Moreover, we found these inhibitors were active against other viruses, including α- and β-CoVs with EC~50~ of 1.1--17.7 μM, but were less potent (higher EC~50~) in killing human β-CoV OC43. Although not as potent as inhibiting picornavirus EV71 with the EC~50~ of 18 and 7 nM for **6c** and **6d**, respectively ([@bib20]), they are the most potent inhibitors of live MERS-CoV identified so far. Their inhibitory activities against picornaviruses and CoVs make these compounds broad-spectrum antiviral agents. With the escalating cost of drug discovery, development of an antiviral agent with broad-spectrum activities might help in overcoming financial hurdles. More compounds are being synthesized for lead optimization. Animal study needs to be further conducted for developing one of these potent inhibitors into an antiviral drug.
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